Klotho Peptide
The 'longevity protein' — a soluble Klotho fragment that extends lifespan in mice, enhances cognition across species, and declines with aging, making it a leading target for anti-aging therapeutics.
The shed ectodomain of α-Klotho, a type I transmembrane protein predominantly expressed in kidney and brain, which circulates as a soluble hormone-like factor that enhances cognition, suppresses aging-related signaling (Wnt, insulin/IGF-1), and promotes synaptic plasticity via GluN2B/NMDA receptor enrichment.
Mechanism of action
Multiple mechanisms: (1) Inhibits insulin/IGF-1 signaling, activating FOXO transcription factors and promoting stress resistance; (2) Suppresses Wnt signaling, reducing cellular senescence and fibrosis; (3) Enhances synaptic plasticity by increasing GluN2B-containing NMDA receptor trafficking to the synapse; (4) Regulates FGF23-mediated phosphate metabolism in kidney; (5) Reduces oxidative stress via Nrf2 activation.
Primary uses
- Longevity and aging research
- Cognitive enhancement studies
- Kidney disease biomarker
- Anti-aging therapeutic development
Typical dosing
Research compound. No human therapeutic dosing established. Mouse studies: 10 mcg/kg IP injection.
Regulatory status
Not approved. Active preclinical research at UCSF (Bhatt lab), Stanford, and others. Recombinant Klotho injection improves cognition in aged mice and nonhuman primates (Nature 2023).
References
- [pubmed] Kurosu H, et al. "Suppression of aging in mice by the hormone Klotho." Science, 2005;309:1829-1833.
- [pubmed] Castner SA, et al. "Longevity factor klotho enhances cognition in aged nonhuman primates." Nat Aging, 2023;3:931-937.
Related peptides
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.